Effect and Potential Mechanism of First-Line Oral Antitubercular Therapy Safety and Effectiveness with Adjuvant Drugs
Main Article Content
Abstract
The purpose of this study is to examine the impact of adjuvant drugs on the safety and efficacy of first-line oral antitubercular therapy. This study was conducted at the pulmonary medicine outpatient department in Delhi, India, and was prospective and non-interventional. Adverse events occurred in 9 patients (18.75%) who did not take metformin and in 7 patients (14.58%) who did take it. (Chi-square test, P=.84) There was no discernible difference between the two groups. All of the reported side effects and problems involved the digestive system and were rather minor in nature. Given that our results suggest metformin might be used as an adjuvant antitubercular drug, particularly in those who have had both diabetes and TB, they are important for many stakeholders and policymakers.
Article Details
References
ADA. Standards of medical care in diabetes-2015. Summary of revisions. Diabetes care 015;38(Suppl):S4.
Lange, C., Dheda, K., Chesov, D., Mandalakas, A. M., & Udwadia, Z. (2019). Management of drug-resistant tuberculosis. The Lancet Respiratory Medicine, 7(9), 820-832.
Mase, S. R., Ramsay, A., Ng, V., Henry, M., Hopewell, P. C., Cunningham, J., & Urbanczik, R. (2013). Yield of serial sputum specimen examinations in the diagnosis of tuberculosis: a systematic review. International Journal of Tuberculosis and Lung Disease, 17(1), 44-52.
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., ... & Phillips, P. P. (2016). Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases, 63(7), 853-867.
Siddiqui AN, Hussain S, Siddiqui N, Khayyam KU, Tabrez S, Sharma M. Detrimental association between diabetes and tuberculosis: An unresolved double trouble. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018 Nov 1;12(6):1101-7.
Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, Tsenova L, Kurepina N, Chen J, Zolezzi F, Kreiswirth B. Metformin as adjunct antituberculosis therapy. Science translational medicine. 2014 Nov 19;6(263):263ra159.
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., ... & Villarino, M. E. (2019). Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. Recommendations and reports: Morbidity and mortality weekly report.
Sugawara I, Yamada H, Mizuno S. Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats. The Tohoku journal of experimental medicine. 2004;204(2):135-45.
Thillai M, Pollock K, Pareek M, Lalvani A. Interferon-gamma release assays for tuberculosis: current and future applications. Expert Review of Respiratory Medicine. 2014 Feb 1;8(1):67-78.
World Health Organization. (2019). WHO consolidated guidelines on tuberculosis: Module 4: Treatment: Drug-resistant tuberculosis treatment. Geneva: World Health Organization. Retrieved from
Yew WW, Chang KC, Chan DP, Zhang Y. Metformin as a host-directed therapeutic in tuberculosis: is there a promise?. Tuberculosis. 2019 Mar 1;115:76- 80.